Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | HPN | P05981 | 1/20 | 0.43 |
| ▸ | SDCBP | O00560 | 1/20 | 0.43 |
| ▸ | SDC2 | P34741 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.41 |
| ▸ | PPID | Q08752 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15729229 | 0.85 | HDAC1 (0.52) | HDAC1L3MBTL1AAK1NAMPTAKT1 | |
| SCHEMBL506891 | 0.82 | CYP17A1 (0.61) | HDAC1L3MBTL1NAMPTAKT1CYP17A1 | |
| SCHEMBL14352914 | 0.80 | ALDH2 (0.57) | — | |
| SCHEMBL14352861 | 0.78 | ALDH2 (0.56) | — | |
| SCHEMBL3180689 | 0.77 | L3MBTL1 (0.61) | HDAC1L3MBTL1NAMPTSDCBPSDC2 | |
| SCHEMBL2567630 | 0.76 | HDAC1 (0.57) | HDAC1L3MBTL1NAMPTCYP17A1HPN | |
| SCHEMBL14477706 | 0.76 | SLC13A5 (0.41) | AAK1MAPTSLC13A5 | |
| SCHEMBL1691047 | 0.76 | HDAC1 (0.67) | HDAC1L3MBTL1NAMPTSDCBPSDC2 | |
| SCHEMBL31717419 | 0.76 | HDAC1 (0.51) | HDAC1L3MBTL1NAMPTGRM2MAPT | |
| SCHEMBL10165065 | 0.76 | LOX (0.48) | L3MBTL1AAK1NAMPTBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180338989-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2018-11-29 | — | — | US | disclosed |
| US-9987295-B2 | Compounds for the treatment of addiction | AMYGDALA NEUROSCIENCES, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9987295-B2 | Compounds for the treatment of addiction | AMYGDALA NEUROSCIENCES, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-2993170-B1 | N-[4-(2-OXO-1,2-DIHYDRO-PYRIDIN-4-YL)-BENZYL]-BENZAMIDE DERIVATIVES AS ALDH-2 INHIBITORS FOR THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2993170-B1 | N-[4-(2-OXO-1,2-DIHYDRO-PYRIDIN-4-YL)-BENZYL]-BENZAMIDE DERIVATIVES AS ALDH-2 INHIBITORS FOR THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170266210-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170266210-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9610299-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9610299-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| EP-2993170-A1 | N-[4-(2-OXO-1,2-DIHYDRO-PYRIDIN-4-YL)-BENZYL]-BENZAMIDE DERIVATIVES AS ALDH-2 INHIBITORS FOR THE TREATMENT OF ADDICTION | Gilead Sciences, Inc. (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20140051668-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051668-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8575353-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575353-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8558001-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8558001-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130203704-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203704-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2013006400-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| US-20130005689-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180338989-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | HDAC1 160/4885L3MBTL1 3214/4885AAK1 1414/4885 |
| US-20130203704-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | HDAC1 160/4885L3MBTL1 3214/4885AAK1 1414/4885 |
| US-20140051668-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | HDAC1 160/4885L3MBTL1 3214/4885AAK1 1414/4885 |
| US-20130005689-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | HDAC1 160/4885L3MBTL1 3214/4885AAK1 1414/4885 |
| US-20170266210-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | HDAC1 160/4885L3MBTL1 3214/4885AAK1 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.